Jennison Associates LLC reduced its position in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 9.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,773,275 shares of the biopharmaceutical company’s stock after selling 180,121 shares during the quarter. Jennison Associates LLC owned about 10.19% of Assembly Biosciences worth $61,923,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Nationwide Fund Advisors acquired a new stake in shares of Assembly Biosciences in the 2nd quarter worth $161,000. Parametric Portfolio Associates LLC increased its stake in shares of Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 1,203 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Assembly Biosciences in the 2nd quarter worth $212,000. Wells Fargo & Company MN acquired a new stake in shares of Assembly Biosciences in the 2nd quarter worth $213,000. Finally, Trexquant Investment LP acquired a new stake in shares of Assembly Biosciences in the 2nd quarter worth $217,000. 62.19% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/jennison-associates-llc-sells-180121-shares-of-assembly-biosciences-inc-asmb/1702485.html.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $33.70, for a total value of $33,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 19.60% of the stock is owned by company insiders.

A number of brokerages have issued reports on ASMB. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Jefferies Group LLC began coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Finally, BidaskClub raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th.

Shares of Assembly Biosciences, Inc. (ASMB) opened at $33.34 on Tuesday. Assembly Biosciences, Inc. has a 52 week low of $11.07 and a 52 week high of $36.31.

Assembly Biosciences Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.